We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Association Between Body Size Phenotypes and Subclinical Atherosclerosis.
- Authors
Rossello, Xavier; Fuster, Valentin; Oliva, Belén; Sanz, Javier; Fernández Friera, Leticia A.; López-Melgar, Beatriz; Mendiguren, José María; Lara-Pezzi, Enrique; Bueno, Héctor; Fernández-Ortiz, Antonio; Ibanez, Borja; Ordovás, José María
- Abstract
<bold>Context: </bold>The underlying relationship between body mass index (BMI), cardiometabolic disorders, and subclinical atherosclerosis is poorly understood.<bold>Objective: </bold>To evaluate the association between body size phenotypes and subclinical atherosclerosis.<bold>Design: </bold>Cross-sectional.<bold>Setting: </bold>Cardiovascular disease-free cohort.<bold>Participants: </bold>Middle-aged asymptomatic subjects (n = 3909). A total of 6 cardiometabolic body size phenotypes were defined based on the presence of at least 1 cardiometabolic abnormality (blood pressure, fasting blood glucose, triglycerides, low high-density lipoprotein cholesterol, homeostasis model assessment-insulin resistance index, high-sensitivity C-reactive protein) and based on BMI: normal-weight (NW; BMI <25), overweight (OW; BMI = 25.0-29.9) or obese (OB; BMI >30.0).<bold>Main Outcome Measures: </bold>Subclinical atherosclerosis was evaluated by 2D vascular ultrasonography and noncontrast cardiac computed tomography.<bold>Results: </bold>For metabolically healthy subjects, the presence of subclinical atherosclerosis increased across BMI categories (49.6%, 58.0%, and 67.7% for NW, OW, and OB, respectively), whereas fewer differences were observed for metabolically unhealthy subjects (61.1%, 69.7%, and 70.5%, respectively). When BMI and cardiometabolic abnormalities were assessed separately, the association of body size phenotypes with the extent of subclinical atherosclerosis was mostly driven by the coexistence of cardiometabolic risk factors: adjusted OR = 1.04 (95% confidence interval [CI], 0.90-1.19) for OW and OR = 1.07 (95% CI, 0.88-1.30) for OB in comparison with NW, whereas there was an increasing association between the extent of subclinical atherosclerosis and the number of cardiometabolic abnormalities: adjusted OR = 1.21 (95% CI, 1.05-1.40), 1.60 (95% CI, 1.33-1.93), 1.92 (95% CI, 1.48-2.50), and 2.27 (95% CI, 1.67-3.09) for 1, 2, 3, and >3, respectively, in comparison with noncardiometabolic abnormalities.<bold>Conclusions: </bold>The prevalence of subclinical atherosclerosis varies across body size phenotypes. Pharmacologic and lifestyle interventions might modify their cardiovascular risk by facilitating the transition from one phenotype to another.
- Subjects
BODY size; CARDIOVASCULAR diseases risk factors; OBESITY; ATHEROSCLEROSIS; CARDIOVASCULAR diseases; PROGNOSIS; PHENOTYPES
- Publication
Journal of Clinical Endocrinology & Metabolism, 2020, Vol 105, Issue 12, p1
- ISSN
0021-972X
- Publication type
journal article
- DOI
10.1210/clinem/dgaa620